Edgewise Therapeutics , Inc. (NASDAQ:EWTX), with a market capitalization of $2.67 billion, is a biopharmaceutical company focused on developing innovative therapies for severe, rare muscle disorders.

Edgewise Therapeutics , Inc. (NASDAQ:EWTX), with a market capitalization of $2.67 billion, is a biopharmaceutical company focused on developing innovative therapies for severe, rare muscle disorders.

In this article, we are going to take a look at where Edgewise Therapeutics, Inc. (NASDAQ:EWTX) stands against Andreas Halvorsen’s other long-term stock picks. Andreas Halvorsen is a prominent ...

For example, Edgewise Therapeutics (NASDAQ:EWTX) shareholders have done very well over the last year, with the share price soaring by 176%. Having said that, unprofitable companies are risky ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Truist Financial analyst Srikripa Devarakonda reiterated a Buy rating on Nurix Therapeutics (NRIX – Research Report) today. The company’s ...

Edgewise Therapeutics has a 12 month low of $9.61 and a 12 month high of $38.12. The firm has a fifty day simple moving average of $29.65 and a 200 day simple moving average of $26.09. Get ...

Presenting at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 1:30 p.m. PT (4:30 p.m. ET) - Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease ...